AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8712441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 1905476 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk (50 g lactose/L)
Number of subjects: 50
Study 1905476 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified milk (24 g lactose/L)
Number of subjects: 50
Study 1905476 — intervention group
Group type: COMPARATOR
Intervention: Commercial lactose-free diet (LFD)
Number of subjects: 50
Study 6650578 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills-training group
Number of subjects: 35
Study 6650578 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching group
Number of subjects: 35
Study 6650578 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 35
Study 31782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-Intensity Continuous Training (VICT)
Number of subjects: 68
Study 31782930 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body Tabata
Number of subjects: 68
Study 31782930 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control (CTL)
Number of subjects: 68
Study 29856692 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) 1,000 mg on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles for six to eight cycles
Number of subjects: 1202
Study 29856692 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (R) 375 mg/m2 on day 1 of each cycle for six to eight cycles
Number of subjects: 1202
Study 29856692 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus chemotherapy (bendamustine)
Number of subjects: 1202
Study 29856692 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus chemotherapy (CHOP)
Number of subjects: 1202
Study 29856692 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus chemotherapy (CVP)
Number of subjects: 1202
Study 29856692 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CHOP)
Number of subjects: 1202
Study 29856692 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (bendamustine)
Number of subjects: 1202
Study 26563148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (5.5-month diet-exercise program with mindfulness training)
Number of subjects: 194
Study 26563148 — intervention group
Group type: COMPARATOR
Intervention: Active control group (5.5-month diet-exercise program without mindfulness training)
Number of subjects: 194
Study 26563148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 194
Study 26563148 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 194
Study 25385735 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 urinary assay
Number of subjects: 859
Study 22017969 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-MPH
Number of subjects: 142
Study 22017969 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 142
Study 19560995 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic muscular strengthening exercises
Number of subjects: 132
Study 19560995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral knee static stretching and isokinetic exercises
Number of subjects: 132
Study 19560995 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) stretching and isokinetic exercises
Number of subjects: 132
Study 19560995 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group IV)
Number of subjects: 132
Study 17620907 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Severity Index
Number of subjects: 486
Study 17620907 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Triage and Acuity Scale
Number of subjects: 486
Study 17620907 — intervention group
Group type: COMPARATOR
Intervention: Emergency Severity Index vs. Canadian Triage and Acuity Scale
Number of subjects: 486
Study 16386090 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 36
Study 16386090 — intervention group
Group type: COMPARATOR
Intervention: Unfixed combination therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride
Number of subjects: 36
Study 16386090 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 11786452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (brief verbal advice and standard booklet)
Number of subjects: 540
Study 11786452 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 540
Study 11786452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (declaration of commitment component)
Number of subjects: 540
Study 9523808 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg intrathecal clonidine with 2.5 microg intrathecal sufentanil
Number of subjects: 98
Study 9523808 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg intrathecal clonidine with 5 microg intrathecal sufentanil
Number of subjects: 98
Study 9523808 — intervention group
Group type: COMPARATOR
Intervention: 5 microg intrathecal sufentanil alone
Number of subjects: 98
Study 7662176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0
Study 2547470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 20
Study 2547470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg daily
Number of subjects: 20
Study 2547470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2547470 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and Ramipril
Number of subjects: 20
Study 821986 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% cromolyn sodium
Number of subjects: 34
Study 821986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31577797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group antenatal care (G-ANC)
Number of subjects: 1844
Study 27098455 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised weekly exercise from the 20th week of pregnancy onwards
Number of subjects: 81
Study 27098455 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 81
Study 27098455 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised weekly exercise
Number of subjects: 81
Study 25714880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rocuronium (1.2 mg/kg)
Number of subjects: 50
Study 25714880 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose rocuronium (0.6 mg/kg)
Number of subjects: 50
Study 25714880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (C and H)
Number of subjects: 50
Study 24091981 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (Dox) and ifosfamide (Ifo) followed by high dose chemotherapy with ifosfamide, carboplatin, etoposide (HD-ICE) plus peripheral blood stem cell transplantation (PBSCT)
Number of subjects: 30
Study 24091981 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with ifosfamide, carboplatin, etoposide (HD-ICE)
Number of subjects: 30
Study 24091981 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus consolidation HD-ICE
Number of subjects: 30
Study 24091981 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose chemotherapy plus external beam radiation therapy (EBRT)
Number of subjects: 30
Study 22123184 — intervention group
Group type: EXPERIMENTAL
Intervention: 6β-naltrexol
Number of subjects: 10
Study 22123184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19620427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% barium sulfate oral suspension (1,350 mL over 60-75 minutes)
Number of subjects: 85
Study 19620427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% barium sulfate oral suspension
Number of subjects: 85
Study 19620427 — intervention group
Group type: COMPARATOR
Intervention: No oral contrast material
Number of subjects: 85
Study 16856570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m MIBI SPECT
Number of subjects: 40
Study 12935792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone hydrochloride (150 mg) three times daily for 8 days
Number of subjects: 20
Study 12935792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10714424 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg as dry powder, 2 x 5 mg blisters via Diskhaler, twice daily on day 1 and four times daily from day 2 to day 14)
Number of subjects: 13
Study 10714424 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 13
Study 10714424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8815686 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alpha therapy
Number of subjects: 300000000
Study 8815686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogues
Number of subjects: 300000000
Study 8815686 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccines and combination therapies
Number of subjects: 300000000
Study 1382256 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) 10 mg/day orally at 7.00 p.m.
Number of subjects: 63
Study 1382256 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 63
Study 3910548 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole (2 X 150 mg pessaries)
Number of subjects: 100
Study 3910548 — intervention group
Group type: COMPARATOR
Intervention: Isoconazole (2 X 300 mg pessaries)
Number of subjects: 100
Study 31671137 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 20
Study 31671137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29285709 — intervention group
Group type: EXPERIMENTAL
Intervention: IWT + dried tofu intake (DTG, n = 16; 111 kcal, 9.6 g protein, 6.0 g fat, and 4.6 g carbohydrate)
Number of subjects: 32
Study 29285709 — intervention group
Group type: COMPARATOR
Intervention: IWT + placebo intake (PLG, n = 16; 108 kcal, 0.2 g protein, 5.5 g fat, and 14.4 g carbohydrate)
Number of subjects: 32
Study 29285709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DTG and PLG)
Number of subjects: 32
Study 26797632 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone‐supplemented probiotic soy product (ISP)
Number of subjects: 49
Study 26797632 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic soy product (SP)
Number of subjects: 49
Study 26797632 — intervention group
Group type: COMPARATOR
Intervention: Unfermented soy product (USP)
Number of subjects: 49
Study 24952387 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message assessments of sleepiness, fatigue, and concentration difficulties, with tailored intervention messages for those reporting high levels of sleepiness or fatigue.
Number of subjects: 0
Study 24952387 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving assessment only text messages.
Number of subjects: 0
Study 22900547 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% cyclosporine A (CsA) eye drops for an average duration of 5.1 ± 3.5 months (1 ‐ 13 months)
Number of subjects: 16
Study 20925493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumping stroke
Number of subjects: 10
Study 20925493 — intervention group
Group type: COMPARATOR
Intervention: Circular stroke
Number of subjects: 10
Study 17982924 — intervention group
Group type: EXPERIMENTAL
Intervention: Open food challenge
Number of subjects: 9
Study 17982924 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 9
Study 16113520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 59
Study 16113520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 11952443 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with realistic information about the upcoming perioperative procedure (group 1)
Number of subjects: 101
Study 11952443 — intervention group
Group type: COMPARATOR
Intervention: Video without surgery-related information (group 2)
Number of subjects: 101
Study 11952443 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (video with realistic information)
Number of subjects: 101
Study 9863864 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (9 Mio IU/d) every 6 weeks (Group A)
Number of subjects: 64
Study 9863864 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (9 Mio IU/d) whenever CD4 cell count dropped below 1.25-fold of baseline (Group B)
Number of subjects: 64
Study 9863864 — intervention group
Group type: COMPARATOR
Intervention: Control group (HAART without IL-2)
Number of subjects: 64
Study 8549944 — intervention group
Group type: EXPERIMENTAL
Intervention: azathioprine (2.5 mg/kg)
Number of subjects: 63
Study 8549944 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study 2225481 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1-29)NH2, 10 micrograms/kg/h
Number of subjects: 5
Study 2225481 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1-29)NH2, 5 micrograms/kg/h
Number of subjects: 5
Study 2225481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 90964 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (5-10 mg intravenously, followed by 200 mg twice a day orally)
Number of subjects: 480
Study 90964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 90964 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 480
Study 30935618 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 67
Study 30935618 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 67
Study 30935618 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet pellet (PP)
Number of subjects: 67
Study 30935618 — intervention group
Group type: COMPARATOR
Intervention: Induced blood clot (BC)
Number of subjects: 67
Study 27637734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg every 24 h for 48 h (standard dose group)
Number of subjects: 166
Study 27637734 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pantoprazole 40 mg every 12 h for 48 h (double-dose group)
Number of subjects: 166
Study 25435217 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 μg ocriplasmin intravitreal injection
Number of subjects: 100
Study 25435217 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 100
Study 23295056 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir-lamivudine combination
Number of subjects: 219
Study 23295056 — intervention group
Group type: COMPARATOR
Intervention: Entecavir monotherapy
Number of subjects: 219
Study 21103669 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 9
Study 21103669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18786751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d, followed by vitamin E 300 mg/d after 6 months, and homocysteine-lowering therapy (folic acid 5 mg/d, pyridoxine 100 mg/d, vitamin B12 1 mg/d) for another year.
Number of subjects: 93
Study 18786751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 16635661 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched alexandrite laser (QSAL)
Number of subjects: 32
Study 16635661 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 32
Study 15609890 — intervention group
Group type: EXPERIMENTAL
Intervention: Citronella repellent
Number of subjects: 198
Study 15609890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 9419397 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2.0 g daily)
Number of subjects: 31
Study 9419397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8126258 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 9
Study 8126258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 9
Study 8126258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3611169 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable implants (polylactide-glycolide copolymer)
Number of subjects: 56
Study 3611169 — intervention group
Group type: COMPARATOR
Intervention: Metal AO plates and screws
Number of subjects: 56
Study 30652982 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral orthosis with routine physical therapy
Number of subjects: 44
Study 30652982 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy alone
Number of subjects: 44
Study 29024857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density negative air ions (30 or 60 min daily exposure)
Number of subjects: 40
Study 29024857 — intervention group
Group type: COMPARATOR
Intervention: Zero-density negative air ions (placebo condition)
Number of subjects: 40
Study 29024857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density negative air ions
Number of subjects: 40
Study 26910503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual treatment with rilpivirine plus boosted darunavir (DRV)
Number of subjects: 60
Study 26910503 — intervention group
Group type: COMPARATOR
Intervention: Triple treatment (standard cART)
Number of subjects: 60
Study 24745586 — intervention group
Group type: EXPERIMENTAL
Intervention: Epileptic students
Number of subjects: 63
Study 24745586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 22324319 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 45
Study 22324319 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia without sedation
Number of subjects: 45
Study 22324319 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with sedation
Number of subjects: 45
Study 22324319 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 45
Study 20127495 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-endoscopic discectomy (group 1)
Number of subjects: 240
Study 20127495 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro discectomy (group 2)
Number of subjects: 240
Study 20127495 — intervention group
Group type: EXPERIMENTAL
Intervention: Open discectomy (group 3)
Number of subjects: 240
Study 20127495 — intervention group
Group type: COMPARATOR
Intervention: All groups (micro-endoscopic, micro, open)
Number of subjects: 240
Study 17063156 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 47
Study 17063156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16203281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Capture 2 (HC2)
Number of subjects: 5026
Study 16203281 — intervention group
Group type: COMPARATOR
Intervention: Polymerase Chain Reaction (PCR)
Number of subjects: 5026
Study 12018757 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 893
Study 12018757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 893
Study 12018757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal system (NTS)
Number of subjects: 893
Study 12018757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bupropion SR and NTS
Number of subjects: 893
Study 10432175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues
Number of subjects: 0
Study 8524716 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 39
Study 8524716 — intervention group
Group type: COMPARATOR
Intervention: Late intervention
Number of subjects: 39
Study 2089297 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg oestriol vaginal cream for 90 days
Number of subjects: 34
Study 2089297 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing cream
Number of subjects: 34
Study 284065 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice and mouthrinse containing fluorides (stannous fluoride and sodium fluoride)
Number of subjects: 0
Study 284065 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice containing amine fluorides and placebo mouthrinse
Number of subjects: 0
Study 284065 — intervention group
Group type: COMPARATOR
Intervention: Mouthrinse containing amine fluorides and placebo dentifrice
Number of subjects: 0
Study 284065 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice containing stannous fluoride and placebo mouthrinse
Number of subjects: 0
Study 284065 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (placebo dentifrice and mouthrinse)
Number of subjects: 0
Study 31757768 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virome analysis
Number of subjects: 0
Study 27885859 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training for 8 months
Number of subjects: 37
Study 27885859 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 37
Study 25012804 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic magnetic sphincter augmentation (MSA)
Number of subjects: 0
Study 25012804 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 0
Study 23652210 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.7 GBq of iodine-¹³¹I
Number of subjects: 136
Study 23652210 — intervention group
Group type: COMPARATOR
Intervention: 1.1 GBq of iodine-¹³¹I
Number of subjects: 136
Study 22106979 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg / Pioglitazone 30 mg
Number of subjects: 377
Study 22106979 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg / Pioglitazone 15 mg
Number of subjects: 377
Study 22106979 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg / Pioglitazone 30 mg
Number of subjects: 377
Study 22106979 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg / Pioglitazone 15 mg
Number of subjects: 377
Study 22106979 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg / Pioglitazone 0 mg
Number of subjects: 377
Study 22106979 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 0 mg / Pioglitazone 30 mg
Number of subjects: 377